LEUKOCARE AG, a
privately-owned specialist company for protein stabilization and
biological surface coating, announced the
signing of a cooperation agreement with Sanofi Pasteur, the vaccines division
of Sanofi. As part of this
cooperation, Sanofi Pasteur will explore LEUKOCARE’s SPS platform technology to
enhance the shelf-life of selected vaccine formulations.
LEUKOCARE’s
Stabilizing and Protecting Solutions (SPS) are employed in the
biopharmaceutical, medical device, and diagnostics industries to enhance the
shelf-life of proteins and to enable terminal sterilization by irradiation or
ethylene oxide. Terminal sterilization allows for a significant reduction in
production costs by avoiding complex aseptic production and at the same time
and improves product safety, as most sources of error can be excluded in one
single step.
LEUKOCARE, www.LEUKOCARE.com
Filed Under: Drug Discovery
